Covid19-Sources

There is a strong coordinated effort by vaccination groups all over the world to put an end to the current crisis of COVID-19. Now sufficient data are…

Finland's epidemic 22 March 2024: the force driving up excess deaths continues to strengthen. In the past 12 months, the momentum — or 'torque' — of excess deaths among those under 25 has more than quadrupled. Strongest growth is seen among 5-9 year olds.1/x pic.twitter.com/vFWMH0cXPi— Ilkka Rauvola (@jukka235) March 22, 2024

Background: Beau’s lines are transverse grooves in the nail plate that result from transient interruption of the growth of the proximal nail matrix after severe disease. The aim of this study is to systematically report all evidence on the association of Beau’s lines with COVID-19 infection or vaccination against COVID-19. Methods: PubMed and Scopus databases were searched up to January 2024 for articles reporting Beau’s lines associated with COVID-19 infection or vaccination for COVID-19. PROSPERO ID: CRD42024496830. Results: PubMed search identified 299 records while Scopus search identified 18 records. After screening the bibliography, nine studies including 35 cases were included in our systematic review. The studies were reported from different areas around the world. Included studies documented Beau’s lines following COVID-19 vaccination (two studies) or after COVID-19 infection (seven studies). High variability was recorded in onset and resolution times among included cases, averaging 3 months and 6 months after COVID-19 infection, respectively. In the two studies reporting Beau’s lines after vaccination, onset was at 7 days and 6 weeks and resolution occurred after 8 and 17 weeks, respectively. Conclusions: To the best of our knowledge, this is the first systematic review reporting the association of Beau’s lines with COVID-19 infection and vaccination. Severe immune response can result in the formation of these nail disorders. Of importance, Beau’s lines represent a potential indicator of prior severe COVID-19 infection or vaccination for COVID-19, as well as a sign of long COVID-19 syndrome.

The COVID-19 pandemic has a significant impact on public health and the estimated number of excess deaths may be more than three times higher than documented in official statistics. Numerous studies have shown an increased risk of severe COVID-19 and ...

The study published in Nature Cardiovascular Research reveals that SARS-CoV-2, the virus causing COVID-19, can directly infect coronary vessels and arterial plaques, heightening the risk of cardiovascular complications like heart attacks and strokes. These findings offer critical insights into the increased long-term cardiovascular risks for COVID-19 survivors and open new avenues for targeted therapies.

Mounting scientific evidence reveals that being infected with SARS-CoV-2 — the virus that causes COVID — profoundly impacts brain health in many ways.

CoV-lineages has 18 repositories available. Follow their code on GitHub.

𝗖𝗢𝗩𝗜𝗗 𝗜𝗦 𝗡𝗢𝗧 𝗔 𝗙𝗟𝗨𝘈 𝘮𝘦𝘨𝘢-𝘵𝘩𝘳𝘦𝘢𝘥 𝘳𝘦𝘲𝘶𝘦𝘴𝘵𝘦𝘥 𝘣𝘺 @gemcarey pic.twitter.com/T6GBuBWPxG— Emmanuel (@ejustin46) March 25, 2024

Journal of Medical Virology is a clinical virology journal focused on the diagnosis, epidemiology, immunology and pathogenesis of human viral infections & diseases.

COVID-19 in pregnant people increases the risk for poor maternal–fetal outcomes. However, COVID-19 vaccination hesitancy remains due to concerns over the vaccine’s potential effects on maternal–fetal outcomes. Here we examine the ...

We examined factors contributing to the transmission of an acute respiratory virus within multi-use facilities, focusing on an outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a movie theater in the Republic of Korea.

An economic evaluation was conducted to predict the economic and clinical burden of vaccinating immunocompromised (IC) individuals aged ≥30 years with mRNA-1273 variant-adapted COVID-19 vaccines in Fall 2023 and Spring 2024 versus BNT162b2 variant-adapted vaccines in France. The number of symptomatic COVID-19 infections, hospitalizations, deaths, and long COVID cases, costs and quality-adjusted life years (QALYs) was estimated using a static decision-analytic model. Predicted vaccine effectiveness (VE) were based on real-world data from prior versions, suggesting higher protection against infection and hospitalization with mRNA-1273 vaccines. VE estimates were combined with COVID-19 incidence and probability of COVID-19 severe outcomes. Uncertainty surrounding VE, vaccine coverage, infection incidence, hospitalization and mortality rates, costs and QALYs were tested in sensitivity analyses. The mRNA-1273 variant-adapted vaccine is predicted to prevent an additional 3,882 infections, 357 hospitalizations, 81 deaths, and 326 long COVID cases when compared to BNT162b2 variant-adapted vaccines in 230,000 IC individuals. This translates to €10.1 million cost-savings from a societal perspective and 645 QALYs saved. Results were consistent across all analyses and most sensitive to variations surrounding VE and coverage. These findings highlight the importance of increasing vaccine coverage, and ability to induce higher levels of protection with mRNA-1273 formulations in this vulnerable population. ### Competing Interest Statement MK is a shareholder in Quadrant Health Economics, Inc., which was contracted by Moderna, Inc. to conduct this study. AL and MM are consultants at Quadrant Health Economics Inc. CD, NE and MU are employees of Moderna France and hold stock/stock options in the company. KJ and EB are employees of Moderna Inc and hold stock/stock options in the company. BD received fees for consultation from Moderna France. ### Funding Statement This study was funded by Moderna, Inc., Cambridge, MA, USA. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes

Background Since March 2020, COVID-19 has evolved from a localized outbreak to a global pandemic. We assessed the seroprevalence of COVID-19 in three towns in the Centre Sud region of Burkina Faso. Methods A population-based cross-sectional survey was conducted in three medium-sized towns in Burkina Faso’s Centre Sud region, from June to July 2021. Subjects aged 16 or over at the time of the survey were considered for this seroprevalence study. The Biosynex COVID-19 BSS rapid test was used to detect immunoglobulin G (IgG) and immunoglobulin M (IgM) against SARS-CoV-2. A standardized questionnaire was also administered to collect additional information. Results A total of 2449 eligible participants (age ≥ 16 years) were identified. Serological tests for COVID-19 were performed in 2155 individuals. Finally, 2143 valid tests were retained and analyzed. Out of the entire sample, 246 positive tests were observed, corresponding to a prevalence of 11.48%. Prevalence was 9.35% (58 cases) in Kombissiri, 12.86% (80 cases) in Manga and 11.99% (108 cases) in Pô. By gender, 13.37% of women (164 cases) tested positive, and 8.95% of men (82 cases). Women accounted for 66.67% of all positive test subjects. The results show a significantly higher seroprevalence in women (P = 0.007), people over 55 years old (P = 0.004), overweight or obese people (P =0.026) and those with drinking water sources at home (0.013). Conclusions The results of this study show that the COVID-19 virus also circulates in the population of medium-sized towns in Burkina Faso, far more than is officially reported in the country. The study also highlighted the greater vulnerability of women to the epidemic, and the challenge of access to water in the face of diseases such as COVID-19. The preventive measures put in place to fight the pandemic must take these different factors into account. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study was funded by ANRS MIE, an antonomous agency of Inserm, and by the French Development Agency (AFD). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Health Ethics Research Committee of the Ministry of Health of Burkina Faso gave approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors.

School reopenings in 2021 and 2022 coincided with the rapid emergence of new SARS-CoV-2 variants in the United States. In-school mitigation efforts va…

Beckman et al. show that SARS-CoV-2 proteins are found in olfactory areas of the brains of rhesus macaques at 7 days post infection. In addition to direct neuronal infection, extensive neuroinflammation and vascular disruptions are observed, and these effects are exacerbated in aged, diabetic animals.

Press release of the Charité – Universitätsmedizin Berlin

Einige Menschen tragen das Coronavirus über einen langen Zeitraum in sich, wie Studien aus Großbritannien und den USA belegen

Wer mit dem Coronavirus erkrankt ist, muss weiter Vergütung erhalten. Selbst dann, wenn die Krankheit symptomlos verläuft. Die Richter am Bundesarbeitsgericht entschieden den Fall eines Produktionsarbeiters.

Recent research shows that bivalent mRNA COVID vaccines do not increase stroke risk, a claim previously unverified large-scale studies.

The coronavirus disease 2019 (COVID-19) pandemic has caused significant medical, social, and economic impacts globally, both in the short and long term. Although most individuals recover within a few days or weeks from an acute infection, some experience longer lasting effects. Data regarding the postacute sequelae of severe acute respiratory...

In children aged 5–11 years, mRNA vaccines are moderately effective against infections with the omicron variant, but are likely to protect well against COVID-19 hospitalisations. Vaccines were reactogenic but probably safe. Findings of this systematic review can serve as a basis for public health policy and individual decision making on COVID-19 vaccination in children aged 5–11 years.

This cohort study analyzes data from 3 commercial claims databases to conduct near–real-time monitoring of health outcomes following BNT162b2 COVID-19 vaccination in the US pediatric population aged 5 to 17 years.

OBJECTIVES:. Vaccination reduces the risk of acute coronavirus disease 2019 (COVID-19) in children, but it is less clear whether it protects against long COVID. We estimated vaccine effectiveness (VE) against long COVID in children aged 5 to 17 years.METHODS:. This retrospective cohort study used data from 17 health systems in...

This study uses data from 3 prospective cohort studies conducted in the US to assess vaccine effectiveness of bivalent COVID-19 vaccines against SARS-CoV-2 infection and symptomatic COVID-19 among children and adolescents.

Background: The efficacy of the BNT162b2 vaccine in pediatrics was assessed by randomized trials before the Omicron variant’s emergence. The long-term durability of vaccine protection in this population during the Omicron period remains limited. Objective: To assess the effectiveness of BNT162b2 in preventing infection and severe diseases with various strains of the SARS-CoV-2 virus in previously uninfected children and adolescents. Design: Comparative effectiveness research accounting for underreported vaccination in 3 study cohorts: adolescents (12 to 20 years) during the Delta phase and children (5 to 11 years) and adolescents (12 to 20 years) during the Omicron phase. Setting: A national collaboration of pediatric health systems (PEDSnet). Participants: 77 392 adolescents (45 007 vaccinated) during the Delta phase and 111 539 children (50 398 vaccinated) and 56 080 adolescents (21 180 vaccinated) during the Omicron phase. Intervention: First dose of the BNT162b2 vaccine versus no receipt of COVID-19 vaccine. Measurements: Outcomes of interest include documented infection, COVID-19 illness severity, admission to an intensive care unit (ICU), and cardiac complications. The effectiveness was reported as (1-relative risk)*100, with confounders balanced via propensity score stratification. Results: During the Delta period, the estimated effectiveness of the BNT162b2 vaccine was 98.4% (95% CI, 98.1% to 98.7%) against documented infection among adolescents, with no statistically significant waning after receipt of the first dose. An analysis of cardiac complications did not suggest a statistically significant difference between vaccinated and unvaccinated groups. During the Omicron period, the effectiveness against documented infection among children was estimated to be 74.3% (CI, 72.2% to 76.2%). Higher levels of effectiveness were seen against moderate or severe COVID-19 (75.5% [CI, 69.0% to 81.0%]) and ICU admission with COVID-19 (84.9% [CI, 64.8% to 93.5%]). Among adolescents, the effectiveness against documented Omicron infection was 85.5% (CI, 83.8% to 87.1%), with 84.8% (CI, 77.3% to 89.9%) against moderate or severe COVID-19, and 91.5% (CI, 69.5% to 97.6%) against ICU admission with COVID-19. The effectiveness of the BNT162b2 vaccine against the Omicron variant declined 4 months after the first dose and then stabilized. The analysis showed a lower risk for cardiac complications in the vaccinated group during the Omicron variant period. Limitation: Observational study design and potentially undocumented infection. Conclusion: This study suggests that BNT162b2 was effective for various COVID-19–related outcomes in children and adolescents during the Delta and Omicron periods, and there is some evidence of waning effectiveness over time. Primary Funding Source: National Institutes of Health.

About 6 million children in the US might be living with post–COVID-19 condition, also known as long COVID. A recent narrative review in Pediatrics parsed the existing research from the past 3 years about how long COVID presents in children and what the risk factors are for developing the condition.

Nature - Evaluation of evidence generated to test 19 proposed policy recommendations and guidance for the future.

Long COVID is a thorn in the side of "back to normal." Attempts to silence patients are intensifying.

New research indicates that antibiotics can effectively target bacteria in the gut that harbor the virus that causes COVID-19 and produce toxin-like peptides that contribute to COVID-19-related symptoms.

Silver Spring/Maryland – Der Verdacht, dass die Impfung mit dem bivalenten Booster des mRNA-Impfstoffs von Biontech/Pfizer einen Schlaganfall auslösen kann, hat...